ClinicalTrials.gg
CompletedNCT04979806Updated May 22, 2026Results posted

Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

A Phase 3 interventional study of Cefepime-zidebactam (FEP-ZID) and Meropenem in Complicated Urinary Tract Infection and Acute Pyelonephritis, sponsored by Wockhardt. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Wockhardt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with cUTI or AP.

Approximately 528 hospitalized adult subjects (≥ 18 years of age) diagnosed with cUTI or AP will be enrolled in the study. The diagnosis of cUTI or AP will be based on a combination of clinical symptoms and signs plus the presence of pyuria. The total duration of treatment with study drug is 7 to 10 days. Each subject must remain hospitalized during the study drug treatment period; no outpatient parenteral antibiotic therapy is allowed.

02

Conditions studied

  • Complicated Urinary Tract Infection
  • Acute Pyelonephritis
03

In context

Pyelonephritis

79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.

This study's enrollment of 530 is above the median of 175 across 62 interventional studies indexed under Pyelonephritis.

Browse Pyelonephritis studies →

Lead sponsor

Wockhardt is the lead sponsor of 39 studies on the registry; 3 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age
  2. Provide a signed written prior to any study-specific procedures
  3. Meet the clinical criteria for either cUTI or AP
  4. Requires hospitalization to manage the cUTI or AP
  5. Agrees to use effective methods of

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected disease that may confound the assessment of efficacy.
  2. Receipt of more than 72 hours of prior antibiotic therapy except for those failing prior antibiotic therapy and/or having documented uropathogen resistant to the prior therapy.
  3. Rapidly progressive illness such that the subject is unlikely to survive the study period.
  4. Pregnant or breastfeeding women
  5. History of a seizure disorder requiring current treatment
  6. \< 15 mL/min or on renal dialysis
  7. Neutropenia or elevated liver enzymes
  8. to beta-lactam antibiotics
  9. Unlikely to comply with the protocol or the Investigator considers that study participation may not be optimal for the subject
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
530 participants (actual)

Study arms

  • Experimental
    Cefepime-zidebactam (FEP-ZID)

    Drug: Cefepime-zidebactam (FEP-ZID)

  • Active comparator
    Meropenem

    Drug: Meropenem

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Overall Success at Test-of-Cure

    Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 colony forming units or CFU/mL)

    Time frame: Test Of Cure Visit (Day 17 ± 2 days)

  2. Percentage of Subjects With Treatment-Emergent Adverse Events (TEAE)

    Collection of number of adverse events.

    Time frame: Day 1 to the end of study Late Follow-Up visit (LFU) (26 ± 2 days)]

Secondary outcomes

  1. Percentage of Subjects With Overall Success at End-of-Treatment

    Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (\<1000 CFU/mL)

    Time frame: End of Treatment Visit (Day 7 - 10 ± 1 day)

  2. Percentage of Subjects With Clinical Cure at End-of-Treatment

    Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)(CFU)/mL.

    Time frame: End of Treatment Visit (Day 7 - 10 ± 1 day)

  3. Percent of Subjects With Microbiological Eradication at End-of-Treatment

    Microbiologic eradication is defined as demonstrating \<1000 CFU/mL of the bacterial pathogen found at study entry

    Time frame: End of Treatment Visit (Day 7 - 10 ± 1 day)

  4. Percentage of Subjects With Clinical Cure at Test-of-Cure

    Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)

    Time frame: Test-of-Cure (Day 17+-2)

  5. Percent of Subjects With Microbiological Eradication at Test-of-Cure

    Microbiologic eradication is defined as demonstrating \<1000 CFU/mL of the bacterial

    Time frame: Test-of-Cure (Day 17 ± 2 days)

  6. Percentage of Subjects With Clinical Cure at Late Follow-up

    Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)

    Time frame: Late Follow-up (Day 26 ± 2 days)

  7. Plasma Concentration of FEP-ZID

    Plasma samples from ZID-FEP-treated subjects were analyzed to determine concentrations of ZID and FEP using a validated assay. Pharmacokinetic analyses were based on the PK populations at pre-specified time points on Days 1 and 3 (+1).

    Time frame: On Days 1 and 3 (+1) of dosing prior to infusion, within 15 minutes after the end of infusion, and at 3 timepoints up to 7 hours hours post infusion

07

Results

Posted May 22, 2026

Participant flow

Participant flow — Overall Study
MilestoneCefepime-zidebactam (FEP-ZID)Meropenem
Started353177
Completed344174
Not completed93

Outcome measures

PrimaryPercentage of Subjects With Overall Success at Test-of-Cure

Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 colony forming units or CFU/mL)

Time frame:
Test Of Cure Visit (Day 17 ± 2 days)
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Success at Test-of-Cure
ParticipantsCefepime-zidebactam (FEP-ZID)Meropenem
Overall Success at TOC in mMITT-STIC Population25093
Overall Failure/Indeterminate at TOC in mMITT-STIC Population3143
PrimaryPercentage of Subjects With Treatment-Emergent Adverse Events (TEAE)

Collection of number of adverse events.

Time frame:
Day 1 to the end of study Late Follow-Up visit (LFU) (26 ± 2 days)]
Reported as:
Count of participants · Participants
Percentage of Subjects With Treatment-Emergent Adverse Events (TEAE)
ParticipantsCefepime-zidebactam (FEP-ZID)Meropenem
Percentage of Subjects With Treatment-Emergent Adverse Events (TEAE)11250
SecondaryPercentage of Subjects With Overall Success at End-of-Treatment

Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (\<1000 CFU/mL)

Time frame:
End of Treatment Visit (Day 7 - 10 ± 1 day)
Reported as:
Count of participants · Participants
Percentage of Subjects With Overall Success at End-of-Treatment
ParticipantsCefepime-zidebactam (FEP-ZID)Meropenem
Overall Success at End of Treatment (EOT) (mMITT-STIC Population)270132
Overall Failure/Indeterminate at End of Treatment (EOT) (mMITT-STIC Population)114
SecondaryPercentage of Subjects With Clinical Cure at End-of-Treatment

Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)(CFU)/mL.

Time frame:
End of Treatment Visit (Day 7 - 10 ± 1 day)
Reported as:
Count of participants · Participants
Percentage of Subjects With Clinical Cure at End-of-Treatment
ParticipantsCefepime-zidebactam (FEP-ZID)Meropenem
Clinical Response at End of Treatment (EOT) (mMITT-STIC Population)274133
Clinical Non-Response/Indeterminate at End of Treatment (EOT) (mMITT-STIC Population)73
SecondaryPercent of Subjects With Microbiological Eradication at End-of-Treatment

Microbiologic eradication is defined as demonstrating \<1000 CFU/mL of the bacterial pathogen found at study entry

Time frame:
End of Treatment Visit (Day 7 - 10 ± 1 day)
Reported as:
Count of participants · Participants
Percent of Subjects With Microbiological Eradication at End-of-Treatment
ParticipantsCefepime-zidebactam (FEP-ZID)Meropenem
Microbiological Eradication at End of Treatment (EOT) (mMITT-STIC population)276134
Microbiological Persistence/Microbiological Indeterminate at (EOT) (mMITT-STIC population)52
SecondaryPercentage of Subjects With Clinical Cure at Test-of-Cure

Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)

Time frame:
Test-of-Cure (Day 17+-2)
Reported as:
Count of participants · Participants
Percentage of Subjects With Clinical Cure at Test-of-Cure
ParticipantsCefepime-zidebactam (FEP-ZID)Meropenem
Clinical Cure at Test of Cure (TOC)(mMITT-STIC)272129
Clinical Failure/Indeterminate at Test of Cure (TOC)(mMITT-STIC)97
SecondaryPercent of Subjects With Microbiological Eradication at Test-of-Cure

Microbiologic eradication is defined as demonstrating \<1000 CFU/mL of the bacterial

Time frame:
Test-of-Cure (Day 17 ± 2 days)
Reported as:
Count of participants · Participants
Percent of Subjects With Microbiological Eradication at Test-of-Cure
ParticipantsCefepime-zidebactam (FEP-ZID)Meropenem
Microbiologic eradication at Test of Cure (TOC) (mMITT-STIC population)25696
Microbiologic persistence/indeterminate at Test of Cure (TOC) (mMITT-STIC population)2540
SecondaryPercentage of Subjects With Clinical Cure at Late Follow-up

Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)

Time frame:
Late Follow-up (Day 26 ± 2 days)
Reported as:
Count of participants · Participants
Percentage of Subjects With Clinical Cure at Late Follow-up
ParticipantsCefepime-zidebactam (FEP-ZID)Meropenem
Sustained Clinical Cure at Late Follow-up (LFU) in mMITT-STIC population264128
Clinical Failure/ Clinical Indeterminate at Late Follow-up (LFU) in mMITT-STIC population81
SecondaryPlasma Concentration of FEP-ZID

Plasma samples from ZID-FEP-treated subjects were analyzed to determine concentrations of ZID and FEP using a validated assay. Pharmacokinetic analyses were based on the PK populations at pre-specified time points on Days 1 and 3 (+1).

Time frame:
On Days 1 and 3 (+1) of dosing prior to infusion, within 15 minutes after the end of infusion, and at 3 timepoints up to 7 hours hours post infusion
Reported as:
Mean · ug/mL
Plasma Concentration of FEP-ZID
ug/mLCefepime (FEP)Zidebactam (ZID)
Day 1 at 0.25 hours89.400 ± 104.66544.941 ± 49.569
Day 1 at 2 hours47.375 ± 21.52224.461 ± 11.252
Day 3 at 0.5 hours19.297 ± 17.79810.250 ± 9.693
Day 3 at 2 hours61.836 ± 47.28131.866 ± 22.947
Day 3 at 4 hours38.750 ± 24.52220.261 ± 13.319
Day 3 at 7 hours23.278 ± 19.03912.378 ± 10.849
Day 4 at 0.5 Hours15.709 ± 7.9988.107 ± 4.716
Day 4 at 2 Hours54.351 ± 19.33128.329 ± 10.052
Day 4 at 4 Hours30.469 ± 9.96315.664 ± 5.529
Day 4 at 7 Hours19.173 ± 8.7929.825 ± 5.029

Adverse events

Collected over Through study completion, from the signing of the Informed Consent Form (ICF) to the Late Follow-Up (LFU) visit, approximately 28 days per participant.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cefepime-zidebactam (FEP-ZID)0/352 (0%)8/352 (2.3%)35/352 (9.9%)
Meropenem0/177 (0%)1/177 (0.6%)19/177 (10.7%)
Most frequent serious events
Most frequent serious events
EventCefepime-zidebactam (FEP-ZID)Meropenem
Pseudomembranous colitisInfections and infestations3/3520/177
Mechanical ileusGastrointestinal disorders0/3521/177
Anaphylactic reactionImmune system disorders1/3520/177
COVID-19Infections and infestations1/3520/177
Thoracic vertebral fractureInjury, poisoning and procedural complications1/3520/177
HyperglycaemiaMetabolism and nutrition disorders1/3520/177
Urethral stenosisRenal and urinary disorders1/3520/177
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCefepime-zidebactam (FEP-ZID)Meropenem
HeadacheNervous system disorders11/3529/177
DiarrhoeaGastrointestinal disorders15/3527/177
NauseaGastrointestinal disorders3/3526/177
HYPERTENTIONCardiac disorders11/3522/177
HypokalaemiaMetabolism and nutrition disorders10/3522/177
ConstipationGastrointestinal disorders5/3522/177
Abdominal pain upperGastrointestinal disorders4/3521/177
HematuriaRenal and urinary disorders4/3520/177
PainGeneral disorders0/3522/177
Decreased AppetiteMetabolism and nutrition disorders2/3522/177

Baseline characteristics

Baseline Analysis Population described here includes MITT (modified intend to treat)

Age, Customized
Age, Customized(Participants)Cefepime-zidebactam (FEP-ZID)MeropenemTotal
>=18 years in MITT population352177529
Sex: Female, Male
Sex: Female, Male(Participants)Cefepime-zidebactam (FEP-ZID)MeropenemTotal
Female15579234
Male19798295
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cefepime-zidebactam (FEP-ZID)MeropenemTotal
White311158469
Asian Non Chinese9313106
Asian Chinese12517
American Indianor Alaskan Native617
Region of Enrollment
Region of Enrollment(participants)Cefepime-zidebactam (FEP-ZID)MeropenemTotal
United States6410
China12517
Poland362157
Mexico8614
Slovakia12921
Bulgaria16674240
Lithuania672693
Estonia221941
India231336
08

Study locations

48 sites
  • S&D Clinical Research, LLC
    Fort Myers, Florida 33919, United States
  • Santos Research Center
    Tampa, Florida 33615, United States
  • MHAT Dobrich AD
    Dobrich, Bulgaria
  • UMHAT Dr. Georgi Stranski
    Pleven, Bulgaria
  • Multiprofile Hospital for Active Treatment - Plovdiv AD, Plovdiv
    Plovdiv, Bulgaria
  • Multiprofile Hospital for Active Treatment - KANEV
    Rousse, Bulgaria
  • Multiprofile Hospital for Active Treatment (MHAT)- Silistra
    Silistra, Bulgaria
  • Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda EAD
    Sofia, Bulgaria
  • Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Pirogov
    Sofia, Bulgaria
  • UMHAT Aleksandrovska Sofia - Clinic of Urology, Clinic of Anaesthesiology and Intensive Care, Clinic of Clinical Hematology
    Sofia, Bulgaria
  • Multiprofile Hospital for Active Treatment (MHAT) Sveta Anna - Varna
    Varna, Bulgaria
  • Hunan Provincial People's Hospital
    Changsha, China
  • The Second Xiangya Hospital of Central South University
    Changsha, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, 400010, China
  • Deyang People's Hospital
    Deyang, China
  • General hospital of the PLA northern theater command
    Liaoyang, China
  • Fudan University Huashan Hospital
    Shanghai, 200040, China
  • Shaoxing People's Hospital
    Shaoxing, China
  • Ida-Viru Central Hospital
    Kohtla-Järve, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, Estonia
  • West Tallinn Central Hospital
    Tallinn, Estonia
  • Tartu University Hospital
    Tartu, Estonia
  • South-Estonian Hospital Ltd.
    Võru, Estonia
  • Super Speciality Hospital Government Medical College and Hospital
    Aurangabad, Maharashtra 431004, India
  • Supe Hearth & Diabetes Hospital & Research Centre
    Nashik, Maharashtra 422002, India
  • ACE Hospital and Research Centre
    Pune, Maharashtra 411004, India
  • Accord Hospitals
    Pune, Maharashtra 412105, India
  • Aartham Multi Super Speciality Hospital
    Ahmedabad, 380006, India
  • ORIION Citicare Super Speciality Hospital
    Aurangabad, 431005, India
  • Klaipedos university hospital
    Klaipėda, LT-92288, Lithuania
  • Republican Vilnius University hospital
    Vilnius, Lithuania
  • Vilnius city clinical hospital
    Vilnius, Lithuania
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, Lithuania
  • Hospital Angeles Chihuahua
    Chihuahua City, 31238, Mexico
  • JM Research Cuernavaca
    Cuernavaca, 62290, Mexico
  • Centro de Investigacion Clinica de Oaxaca (CICLO)
    Oaxaca City, Mexico
  • Pharmacology & Clinical Research
    Querétaro, Mexico
  • Arke SMO S.A. de C.V.
    Veracruz, Mexico
  • Unidad de Atención Médica e Investigación en Salud (Unamis)
    Yucatán, C.P 97000, Mexico
  • Zespol Opieki Zdrowotnej w Boleslawcu
    Bolesławiec, Poland
  • SCM Sp. z o.o.
    Krakow, 31-559, Poland
  • Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego w Lodzi, Oddzial Nefrologii
    Lodz, 90-153, Poland
  • Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy, Klinika Chorob Wewnetrznych, Nefrologii i Dializoterapii
    Warsaw, Poland
  • Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica
    Banská Bystrica, Slovakia
  • Fakultna nemocnica Nitra
    Nitra, Slovakia
  • Nemocnica Poprad, a.s. Urologicke oddeleni
    Poprad, Slovakia
  • Fakultna nemocnica s poliklinikou Zilina
    Žilina, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Nov 2024, 26 months.

Results were first posted in May 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2021
First posted
Jul 28, 2021
StartActual
Aug 28, 2022
Primary completionActual
Nov 25, 2024
CompletionActual
Nov 25, 2024
Results first posted
May 22, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04979806
Lead sponsor
Wockhardt
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Jul 28, 2021
Start date
Aug 28, 2022
Primary completion
Nov 25, 2024
Completion
Nov 25, 2024
Results posted
May 22, 2026
Last update
May 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cefepime-zidebactam

Start the discussion